Published in Health Business Week, September 15th, 2006
"During the second quarter, we made great strides in advancing our products through the pipeline at all stages as exemplified by Cetrotide's marketing approval in Japan, our successful meeting with the FDA leading to the upcoming filing of an IND to move forward into phase III clinical development of cetrorelix in benign prostatic hyperplasia (BPH), as well as the disclosure of positive clinical results in cancer with perifosine and AN-152. Most recently, we disclosed positive phase II results for ozarelix in prostate cancer which will enable us to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.